EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)Amin Nassar,Elio Adib,Jamie Feng,Jacqueline V. Aredo,Kaushal Parikh,Jeremy Phillip Harris, Ana I. Velazquez Manana,Meera Vimala Ragavan,Jessica Jiyeong Lin,Zofia Piotrowska,Bailey Gleason Fitzgerald,Christian Grohe,Kamya Sankar,Joel W. Neal,Heather A. Wakelee,Frances A. Shepherd,Roy S. Herbst,Abdul Rafeh Naqash,Sarah B. Goldberg, So Yeon KimJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览27暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
